Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

• Published in: Pharmaceutics Vol. 15; no. 9; p. 2363
• Main Authors: Viegas, Cláudia, Patrício, Ana B, Prata, João, Fonseca, Leonor, Macedo, Ana S, Duarte, Sofia O D, Fonte, Pedro
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.09.2023; MDPI
• Subjects: Amino acids; Cancer therapies; Chemical bonds; Chemotherapy; Developing countries; Drug delivery systems; Drugs; Enzymes; Fatalities; Fatty acids; Food; Glucagon; Glucose; Health aspects; hybrid nanoparticle; inorganic nanoparticle; LDCs; lipid nanoparticle; Lipids; Mortality; nanocarrier; Nanoparticles; Nanotechnology; Pancreatic cancer; polymer nanoparticle; Portugal; Review; Small intestine; Toxicity; Triglycerides; Tumors; Vehicles; Portugal; nanocarrier; lipid nanoparticle; pancreatic cancer; hybrid nanoparticle; polymer nanoparticle; inorganic nanoparticle
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15092363

Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized.